These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 1689220)

  • 1. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow.
    Keever CA; Welte K; Small T; Levick J; Sullivan M; Hauch M; Evans RL; O'Reilly RJ
    Blood; 1987 Dec; 70(6):1893-903. PubMed ID: 3118990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursors.
    Ballas ZK; Rasmussen W
    Cell Immunol; 1991 May; 134(2):296-313. PubMed ID: 1827045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomagnetic isolation of NK and LAK cells.
    Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
    J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
    Anderson PM; Bach FH; Ochoa AC
    Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
    Whiteside TL; Wang YL; Selker RG; Herberman RB
    Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis.
    Kantor TV; Whiteside TL; Friberg D; Buckingham RB; Medsger TA
    Arthritis Rheum; 1992 Jun; 35(6):694-9. PubMed ID: 1376124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
    Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
    Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
    Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
    Yarbrough WC; Weissler JC
    Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
    Drobyski WR; LeFever AV; Truitt RL
    Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.